Browsing "Li Ka Shing Faculty of Medicine: Conference papers" by Author hurwitz, h

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 10 of 10
TitleAuthor(s)Issue DateViews
 
Biomarker modulation in patients (pts) receiving TRC105 (T) and bevacizumab (B) in a phase Ib clinical trial
Proceeding/Conference:Journal of Clinical Oncology
Liu, YClarke, JStarr, MDBrady, JCPang, HMHRushing, CAlvarez, DAdams, BJTheuer, CPHurwitz, HNixon, AB
2014
 
Coagulation factors in citrated plasma predict for benefit from bevacizumab (B) in patients with advanced pancreatic cancer (APC): Results from CALGB 80303 (Alliance)
Proceeding/Conference:Journal of Clinical Oncology
Clarke, JMPang, HMHStarr, MDHatch, AJKindler, HLO'Reilly, EMInnocenti, FVenook, APHurwitz, HNixon, AB
2015
 
Correlation of Src activation with response to dasatinib, capecitabine, oxaliplatin, and bevacizumab in advanced solid tumors
Proceeding/Conference:Journal of Clinical Oncology
Strickler, JHMcCall, SNixon, ABPang, HMHRushing, CArrowood, CHaley, SMeadows, KHurwitz, H
2013
47
 
Direct Evidence of Targeted Inhibition by Anti-angiogenic Agents from a Wound-healing Model in Patients with Advance Solid Tumors
Proceeding/Conference:Targeting VEGF-mediated Tumor Angiogenesis in Cancer Therapy Conference
Jia, JDellinger, AWeiss, ESBulusu, ALi, HHoward, LKaplan, NPang, HMHHurwitz, HNixon, AB
2014
43
 
Modulation of angiogenic biomarkers in patients receiving high-dose TRC105
Proceeding/Conference:Journal of Clinical Oncology
Liu, YStarr, MBrady, JCPang, HMHDellinger, ALeigh, BRTheuer, CPHurwitz, HNixon, AB
2012
49
 
Modulation of angiogenic biomarkers in patients treated on a phase I study of TRC105 (anti-CD105 antibody) monotherapy for advanced solid tumors
Proceeding/Conference:Journal of Clinical Oncology
Liu, YStarr, MPang, HMHMarcello, JLeigh, BRTheuer, CPHurwitz, HNixon, AB
2011
67
 
Modulation of pharmacodynamic (PD) biomarkers in dermal biopsies from patients treated on a phase I study of bevacizumab (Bev) in combination with everolimus (Ev) and erlotinib (Erl) for advanced solid tumors
Proceeding/Conference:Journal of Clinical Oncology
Jia, JLi, HDellinger, APang, HMHRussell, KBHurwitz, HNixon, AB
2012
49
 
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: Results from CALGB 80303
Proceeding/Conference:Journal of Clinical Oncology
Nixon, ABPang, HMHStarr, MHollis, DFriedman, PNBertagnolli, MMKindler, HLGoldberg, RMVenook, APHurwitz, H
2011
51
 
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance)
Proceeding/Conference:Journal of Clinical Oncology
Hatch, AJPang, HMHStarr, MDBrady, JCJia, JChen, JSibley, AOwzar, KNiedzwiecki, DVenook, APCushman, SMHurwitz, HNixon, AB
2014
 
Use of plasma angiome to predict PFS in patients with metastatic colorectal cancer (mCRC) treated with capecitabine, oxaliplatin, and bevacizumab (XELOX-A)
Proceeding/Conference:Journal of Clinical Oncology
Nixon, AStarr, MPang, HMHBulusu, AHoneycutt, WAmara, ABendell, JCHurwitz, H
2010
Showing results 1 to 10 of 10